Pieter Droppert

Pieter Droppert is a management consultant, lawyer, science writer and editor of the Biotech Strategy Blog (http://biotechstrategyblog.com) on science, innovation and new product development in the pharma & biotech industries.

Recent posts

A Revolution is Taking Place in the Treatment of Blood Cancers
I try to avoid sensationalizing early clinical trial results presented at medical conferences, what’s commonly known as “hype over hope.” But at this year’s annual meeting of the American Society of... Read more »
Is Crowdfunding The Future For Biomedical Research?
Microryza.com (not the catchiest of names) is a crowdfunding platform for research that raises money over the Internet from individuals who are willing to donate small amounts to fund a specific... Read more »
Prostate Cancer Drug Winners and Losers at ASCO GU
The latest clinical research in prostate cancer is being presented at the American Society of Clinical Oncology Genitorinary Cancers Symposium (ASCO GU) in Orlando, FL. Presentations started yesterday, and run through... Read more »
Emerging Challenges of Prostate Cancer Drug Development
The world’s largest cancer meeting of scientists, physicians and industry has just ended in Chicago. The annual meeting of the American Society of Clinical Oncology (ASCO) attracted over 30,000 attendees to... Read more »
J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early
One of the more anticipated clinical trials at this year’s American Society of Clinical Oncology (ASCO) meeting was for Johnson & Johnson’s abiraterone (Zytiga) in prostate cancer patients. This study, known... Read more »